CSL (ASX:CSL) share price falls on broker downgrade

One broker believes the CSL share price may have peaked for the time being…

| More on:
a trader on the stock exchange holds his head in his hands, indicating a share price drop

Image source: Getty Images

The CSL Limited (ASX: CSL) share price is out of form on Wednesday.

At the time of writing, the biotherapeutics giant’s shares are down 2.5% to $293.10.

Why is the CSL share price under pressure on Wednesday?

Today’s weakness in the CSL share price appears to be due to a broker note out of Citi this morning.

According to the note, the broker has downgraded the company’s shares to a neutral rating but retained its $310.00 price target on them.

Based on the current CSL share price, this price target implies potential upside of 5.8% for its shares over the next 12 months. This potential return simply was not enough for the broker to maintain its buy rating.

What did Citi say?

The note reveals that Citi made the move on valuation grounds, believing that the plasma collection market recovery is now fully priced in.

It commented: “We move CSL to Neutral (from Buy) given the outperformance of the stock since March. We remain 15% ahead of consensus for FY23E, and believe that the plasma collection market will normalize this year. Our rating change is purely valuation based.”

It is worth noting that Citi does see some upside risk for the CSL share price. This is from the CSL112 phase III trial result. The broker explained: “Risk to the upside remains if the CSL112 phase III trial result due at the end of CY21 is positive.”

This clinical trial is evaluating the efficacy and safety of CSL112 for the reduction of early recurrent cardiovascular events following an acute myocardial infarction (MI).

What is CSL112?

CSL112 is a novel apolipoprotein A-I infusion therapy that has been shown to have an immediate and significant impact on the ability to remove cholesterol from arteries. The trial aims to enrol more than 17,000 patients from approximately 1,000 medical centres across the world.

CSL notes that cardiovascular disease is the leading cause of death globally, with an estimated 800,000 acute MIs occurring each year in the United States alone. Furthermore, patients who survive an acute MI are at high risk of experiencing early recurrent cardiovascular events. The majority of which occur in the weeks and months following the initial event.

As a result, CSL112 could be a very important and lucrative therapy if all goes to plan.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two children put their hands in the air on a rollercoaster ride.
Share Market News

Why have ASX 200 shares popped then dropped on Monday?

What’s happening to the ASX 200 for it to be volatile?

Read more »

Arrows pointing upwards with a man pointing his finger at one.
Share Market News

Here are the 3 most traded ASX 200 shares on Monday

We take a look at the most traded ASX 200 shares by volume today.

Read more »

A man with a scrappy beard and wearing dark sunglasses and a beanie head covering raises a fist in happy celebration as he sits at is computer in a home environment.
Share Market News

Archer Materials share price leaps 7% on patent news

It's good news today for the ASX materials tech company.

Read more »

A young man has a look of alarm on his face as he turns to see the close up face of a brown grizzly bear that is draped over him as part of a large life-size bear skin rug he is wearing over his shoulders.

Ethereum price rout knocks founder from billionaire’s list. Does he still ‘welcome a bear market’?

The crypto selloff should offer more clarity on which projects are 'long-term sustainable'.

Read more »

A group of market analysts sit and stand around their computers in an open-plan office environment. The central figures are deep in thought about Megaport's recent earnings release
Share Market News

ASX 200 midday update: Elders and Codan rocket, Incitec Pivot disappoints

The ASX 200 index has started the week on a mildly positive note...

Read more »

stylised silhouette of a bear on financial graph background
Share Market News

These are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the ASX 200 on Monday...

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

2 ASX blue-chip shares this top fund manager thinks are good value

Wilson Asset Management offers its thoughts on a couple of blue-chip shares.

Read more »